首页 | 本学科首页   官方微博 | 高级检索  
检索        

非经典肿瘤多药耐药逆转剂的研究进展
引用本文:张海燕,庄俊雪.非经典肿瘤多药耐药逆转剂的研究进展[J].现代药物与临床,2015,30(6):747-752.
作者姓名:张海燕  庄俊雪
作者单位:天津市宝坻区人民医院, 天津 301800;天津市宝坻区人民医院, 天津 301800
摘    要:化疗是肿瘤综合治疗的主要手段之一,多药耐药性的产生是肿瘤化疗中存在的主要问题。开发多药耐药逆转剂逆转肿瘤细胞对现有化疗药物的耐药性将是一种有效的治疗方法。目前已有多种多药耐药逆转剂处于基础和临床试验阶段。主要从谷胱甘肽S转移酶、蛋白激酶C、凋亡通路受阻、拓扑异构酶和DNA修复能力增强等方面介绍非经典的多药耐药逆转剂。

关 键 词:多药耐药逆转剂  谷胱甘肽S转移酶  蛋白激酶C  拓扑异构酶Ⅱ  DNA修复
收稿时间:2015/4/18 0:00:00

Research progress on atypical tumor multidrug resistance reversal agents
ZHANG Hai-yan and ZHUANG Jun-xue.Research progress on atypical tumor multidrug resistance reversal agents[J].Drugs & Clinic,2015,30(6):747-752.
Authors:ZHANG Hai-yan and ZHUANG Jun-xue
Institution:Tianjin Baodi Hospital, Tianjin 301800, China;Tianjin Baodi Hospital, Tianjin 301800, China
Abstract:Chemotherapy plays an essential role in the combined therapy of tumor, while the emergence of multidrug resistance in tumor cells can always lead the therapy to failure. The development of multidrug resistance reversal agents is a promising approach to overcome the resistance of current chemotherapeutic agents. Presently, various kinds of reversal agents have already been in basic and clinical study. The research progress of atypical multidrug resistance reversal agents are summarized from glutathione S-transferases, protein kinase C, block of apoptotic pathways, topoisomerase, and enhancement of DNA repair in this brief review.
Keywords:
本文献已被 CNKI 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号